The Issue comprises of fresh issue of upto 27,00,000 equity shares of the company at an Issue Price of ₹ per equity share. We intend to utilize the net proceeds of the Issue to meet the following objects as approved by the Board of Directors of the company vide their resolution dated May 04, 2026: 1. Repayment of all or a portion of certain outstanding borrowings availed by the company; and 2.
Purpose
Amount
Since the entire fund requirement of will be met from the Net Proceeds hence, no amount is proposed to
₹8.35 Cr
As on March 31, 2026, our total outstanding borrowings amounted to. the company proposes to utilise
₹9.14 Cr
** Sanctioned limit of Cash credit and overdraft facility are and 101 lakhs respectively as at January 31,
₹4.95 Cr
Strengths & Weaknesses
Strengths
✓Experienced promoters and management team with industry knowledge and a track record
✓Asset-light business model and competitive products
✓Scalable Business Model
✓Wide and diverse range of product offerings
✓Strong Supplier and Vendor Relationships
✓Established Distribution Network
✓For further details, see "Our Business" on page 124.
Management & Promoters
A
Amol Laxmikant MujumdarChairman and Managing Director
F
Foreign CompaniesNon-Executive Director
S
Swapan Premprakash KhandelwalWhole-Time Director
P
Prashant Shrikrishna KarkareExecutive Director
A
Avinash Pandurang AmbulkarExecutive Director
P
Prashant Vithalrao RahateNon-Executive Director
M
Mehul Hari RanadeIndependent Director
M
Mumukshu Management Services LLPIndependent Director
R
Renuka Saurabh BoroleIndependent Director
S
Shraddha Kiran KulkarniIndependent Director
I
Indian CompaniesIndependent Director
S
Service ContractsDirector
P
Perquisites TheManaging Director
Shareholding Pattern
Pre-IPO
Category
%
Promoters
79.7%
Public
20.3%
Peer Comparison
Company
P/E
EPS
Goldline PharmaceuticalIPO
—
—
Telephone: + /
91.0x
—
Telephone: +
91.0x
—
MAY *^
14.0x
—
Dated: May
6.0x
—
Pre-IPO Financials
Period
Revenue (Cr)
PAT (Cr)
Net Worth (Cr)
Total Assets (Cr)
December 2025
—
₹0.15 Cr
₹0.11 Cr
—
March 2025
—
—
₹12.36 Cr
—
March 2024
—
—
₹10.35 Cr
—
March 2023
—
—
₹7.86 Cr
—
2013
—
—
₹5.89 Cr
—
About
Goldline Pharmaceuticals is one of the leading companies involved in the marketing of pharmaceutical products under the name Goldline. Its products are divided into 5 segments: 1. Goldline Pharma, which includes specialities like Physicians, Orthopedics, ENT, Chest Physicians, General and Speciality Surgery, Gastroenterology, Neurology, and Urology, 2. Goldline Cardinal, which includes specialities like Physicians, Diabetologists, Endocrinologists, Cardiologists, and General Physicians, 3. Gol
rupiya.io is for research and education only. IPO data is sourced from public disclosures (DRHP/RHP). Not investment advice. Validate with SEBI-regulated disclosures before acting.
